All about ²²⁵Ac
🌍 Warsaw, Poland, 2-6 June 2025
Technical Workshop on Production and Quality Control of ²²⁵Ac Radiopharmaceuticals
What happens when the International Atomic Energy Agency (IAEA), the Institute of Nuclear Chemistry and Technology, and the Joint Research Centre in Karlsruhe join forces to explore ²²⁵Ac?
The answer is an international workshop packed with knowledge, from nuclear chemistry all the way to clinical implementation.
BIOEMTECH was proud to contribute to and sponsor this initiative, joining a global community of experts working with one of the most promising alpha-emitters in cancer therapy.
A few reasons why this workshop had our full alpha-powered attention:
From nucleus to patient: The workshop covered every step in the ²²⁵Ac radiopharmaceutical chain, from (still limited) isotope production, to RLB and QC strategies, to hands-on cell work, preclinical protocols and clinical applications.
Rethinking combinations: It is becoming clear that combination approaches may hold the key to the future of therapeutic strategies. Alpha + chemo? Beta + alpha? The so-called “cocktail therapies” may be the answer to more effective, personalised treatments.
Correlations that count: Dose-effect relationships were front and center, along with image-based parameters such as SUVmax, demonstrating how uniform radiotracer distribution can improve targeting and response prediction.
Hands-on matters: Practical sessions gave participants the chance to explore RLB handling, QC procedures (the good news: HPLC isn’t always critical) and critical safety aspects such as endotoxin testing. Special emphasis was placed on accurate separation of daughter nuclide energy windows and the multi-step radio-TLC workflow: developing, scanning, cutting specific sections, measuring them using a γ-counter and then repeating the measurements at later time points to track the decay and daughter redistribution.
Special congratulations to INCT for celebrating 70 years of research, radiochemistry, and relentless curiosity. Not a bad way to mark a birthday, by pushing the frontiers of targeted alpha therapy! A special nod to the legacy of Marie Skłodowska-Curie, whose name always comes up when the conversation turns to radiochemistry in Poland.